Fulvestrant or an Aromatase Inhibitor (Physician Choice) clinical trials

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

This study looks at a new drug, giredestrant, for advanced breast cancer that's grown despite previous treatments. It compares giredestrant to standard hormone treatments to see if it's safe and works better for patients with ER-positive, HER2-negative cancer.